RedHill Reports Preliminary Positive Data From RHB-104 Pre-clinical Study

(RTTNews) - RedHill Biopharma Ltd. (RDHL) announced preliminary positive data from a pre-clinical study with RHB-104 for the treatment of type 1 diabetes, a chronic autoimmune disease with an unknown cause. The pre-clinical study was designed to evaluate the potential therapeutic effects of RHB-104 using a pre-clinical diabetes model when administered orally. The company said the preliminary data suggests that RHB-104 is effective in treating type 1 diabetes in the study, as measured by blood glucose levels and body weight. Final results and an independent report are expected in the coming weeks.

The company is currently assessing the next steps in the development program, including a possible Phase II proof of concept clinical study for type 1 diabetes.